Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
PLoS One. 2022 Apr 7;17(4):e0266691. doi: 10.1371/journal.pone.0266691. eCollection 2022.
SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- and Class II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) and membrane (M) proteins and others. This prospective COVID-19 Health Action Response for Marines (CHARM) study enabled assessment of T cell responses against S, N and M proteins in symptomatic and asymptomatic SARS-CoV-2 infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly and bimonthly for the next 6 weeks. Study participants who tested positive by qPCR SARS-CoV-2 test were enrolled in an immune response sub-study. FluoroSpot interferon-gamma (IFN-γ) and IL2 responses following qPCR-confirmed infection at enrollment (day 0), day 7 and 14 and more than 28 days later were measured using pools of 17mer peptides covering S, N, and M proteins, or CD4+CD8 peptide pools containing predicted epitopes from multiple SARS-CoV-2 antigens. Among 124 asymptomatic and 105 symptomatic participants, SARS-CoV-2 infection generated IFN-γ responses to the S, N and M proteins that persisted longer in asymptomatic cases. IFN-γ responses were significantly (p = 0.001) more frequent to the N pool (51.4%) than the M pool (18.9%) among asymptomatic but not symptomatic subjects. Asymptomatic IFN-γ responders to the CD4+CD8 pool responded more frequently to the S pool (55.6%) and N pool (57.1%), than the M pool (7.1%), but not symptomatic participants. The frequencies of IFN-γ responses to the S and N+M pools peaked 7 days after the positive qPCR test among asymptomatic (S pool: 22.2%; N+M pool: 28.7%) and symptomatic (S pool: 15.3%; N+M pool 21.9%) participants and dropped by >28 days. Magnitudes of post-infection IFN-γ and IL2 responses to the N+M pool were significantly correlated with IFN-γ and IL2 responses to the N and M pools. These data further support the central role of Th1-biased cell mediated immunity IFN-γ and IL2 responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-based COVID-19 vaccines that include the N and S proteins.
SARS-CoV-2 T 细胞反应与 COVID-19 康复有关,已经在刺突(S)、核衣壳(N)和膜(M)蛋白以及其他蛋白中鉴定出了 I 类和 II 类限制性表位。这项针对 COVID-19 海军健康行动反应(CHARM)的前瞻性研究,使我们能够评估有症状和无症状 SARS-CoV-2 感染参与者针对 S、N 和 M 蛋白的 T 细胞反应。在入组时,所有参与者的 qPCR 检测均为阴性;在接下来的 6 周内,每两周和每两个月进行一次随访。通过 qPCR SARS-CoV-2 检测呈阳性的研究参与者被纳入免疫反应子研究。在入组时(第 0 天)、第 7 天和第 14 天以及 28 天以上通过 qPCR 确认感染后,使用覆盖 S、N 和 M 蛋白的 17 mer 肽池或包含多个 SARS-CoV-2 抗原预测表位的 CD4+CD8 肽池,测量了荧光斑点干扰素-γ(IFN-γ)和白细胞介素 2(IL2)反应。在 124 名无症状和 105 名有症状参与者中,SARS-CoV-2 感染产生了针对 S、N 和 M 蛋白的 IFN-γ 反应,这些反应在无症状病例中持续时间更长。在无症状受试者中,IFN-γ 对 N 池(51.4%)的反应明显(p = 0.001)比 M 池(18.9%)更频繁;但在有症状的受试者中并非如此。无症状的 IFN-γ 应答者对 CD4+CD8 池的反应更频繁地针对 S 池(55.6%)和 N 池(57.1%),而不是 M 池(7.1%),但没有症状的参与者。无症状(S 池:22.2%;N+M 池:28.7%)和有症状(S 池:15.3%;N+M 池:21.9%)参与者的 IFN-γ 反应在 qPCR 检测呈阳性后 7 天达到峰值,然后在 28 天以上下降。感染后 IFN-γ 和 IL2 对 N+M 池的反应幅度与 IFN-γ 和 IL2 对 N 和 M 池的反应幅度显著相关。这些数据进一步支持了 Th1 偏向的细胞介导免疫 IFN-γ 和 IL2 反应,特别是针对 N 蛋白,在控制 COVID-19 症状方面的核心作用,并证明了包含 N 和 S 蛋白的基于 T 细胞的 COVID-19 疫苗是合理的。